Clinical trials: Allogeneic Stem Cell Transplantation
Meniscus Lesion
Sterile Allogeneic Spongioflex® Allograft as Partial Meniscal Replacement After Incomplete Meniscal Loss
The goal of this clinical trial is to learn if partial meniscal replacement can prevent or postpone total meniscal replacement, in adult patients (female/male) with partial meniscal loss.
- Trial name
- NCT06376422
- Testing
- Spongioflex®, non-operated
- Where
- Germany
- Volunteers
- 40 people
- Sponsor
- Sven Behrendt
Acute Leukemia, Allogeneic Hematopoietic Stem Cell Transplantation
The Gut Microbiome in FLT3- AL Undergoing Allo-HSCT With Or Without Sorafenib Maintenance
This prospective trial investigates the effect of sorafenib maintenance therapy in FLT3 negative acute leukemia patients after allo-HSCT in terms of gut microbiome.
- Trial name
- NCT05601895
- Testing
- Sorafenib
- Where
- China
- Volunteers
- 60 people
- Sponsor
- Nanfang Hospital, Southern Medical University
Malignancies, Hematologic
Pretransplant Evaluation by Supportive Care Team for Patients Undergoing HCT for Hematological Malignancies
This is a feasibility study of pre-transplant involvement of a palliative care provider in the setting of HCT. Although this is primarily a feasibility pilot, the investigators will explore how patients are affected by the…
- Trial name
- NCT02321345
- Testing
- Palliative Care Support
- Where
- United States
- Volunteers
- 7 people
- Sponsor
- Medical College of Wisconsin
System; Lupus Erythematosus
Pilot Trial of Mesenchymal Stem Cells for Systemic Lupus Erythematosus
The purpose of this study is to evaluate the safety of mesenchymal stromal cells (MSCs) obtained from umbilical cords for the treatment of adults with active systemic lupus erythematosus (SLE).
- Trial name
- NCT03171194
- Testing
- Low Dose Mesenchymal Stem Cells (MSCs)
- Where
- 2 sites in United States
- Volunteers
- 6 people
- Sponsor
- Medical University of South Carolina
Relapse Leukemia, Allogeneic Stem Cell Transplantation
Immunoevasive Tactics Employed by Myeloid Malignancy After Allogeneic Stem Cell Transplantation
Allogeneic hematopoietic stem cell transplantation (allo-HSCT) is still the only treatment available to cure acute myeloid leukemia and high risk myelodysplasia.
- Conditions
- Relapse Leukemia, Allogeneic Stem Cell Transplantation, Immune Evasion, Tumor
- Trial name
- EVADE (NCT03964922)
- Testing
- blood sample, bone marrow sample
- Volunteers
- 104 people
- Sponsor
- Central Hospital, Nancy, France
Stress, Psychological, Caregivers
Effectiveness of a Stress Reduction Intervention in Caregivers of Allogeneic Hematopoietic Stem Cell Transplant (HSCT) Recipients
Background: People who have an allogeneic hematopoietic stem cell transplant (HSCT) need help as they recover. Being a caregiver can be stressful to the body and mind. Researchers want to find ways to reduce this stress.
- Trial name
- NCT02257853
- Testing
- Stress reduction intervention
- Where
- United States
- Volunteers
- 53 people
- Sponsor
- National Institutes of Health Clinical Center (CC)
Leukemia, Lymphoma
Post Transplant Cyclophosphamide (Cytoxan) for GvHD Prophylaxis
The main purpose of this study is to assess the effects of cyclophosphamide (cytoxan) in the post transplant setting to prevent onset of acute graft-versus-host disease (GVHD).
- Conditions
- Leukemia, Lymphoma, Myelodysplastic Syndrome, Myelofibrosis
- Trial name
- NCT02065154
- Testing
- Cyclophosphamide
- Where
- United States
- Volunteers
- 39 people
- Sponsor
- University of Alabama at Birmingham
Hematologic Malignancy
Donor Stem Cell Transplant in Treating Patients With High-Risk Hematologic Malignancies
The purpose of this research study is to examine the survival of patients undergoing partially matched hematopoietic stem cell transplant (HSCT) on a new type of treatment approach, which has been developed specifically for…
- Trial name
- NCT01341301
- Testing
- Total Body Irradiation, Donor Lymphocyte Infusion (DLI), Cyclophosphamide
- Where
- United States
- Volunteers
- 25 people
- Sponsor
- Sidney Kimmel Comprehensive Cancer Center at Thomas Jefferson University
Brittle Type 1 Diabetes
Allogeneic Transplantation of Expanded Pancreatic Islet Cells
This study will evaluate the efficacy and safety of allogeneic pancreatic islet cells transplantation in patients with "brittle" type 1 diabetes.
- Trial name
- NCT05990530
- Testing
- YD02-2022
- Where
- China
- Volunteers
- 6 people
- Sponsor
- Shanghai Jiao Tong University School of Medicine
Diabetic Foot, Diabetic Foot Ulcer
Study for Treatment of Chronic Diabetic Foot Ulcers With the Investigational Allogeneic Cell Therapy Product, hOMSC200
Purpose of this phase 1/2a study is to assess the safety and efficacy of administration of allogeneic human oral mucosal stem cells (hOMSCs) in patients suffering from chronic diabetic foot ulcers (DFU).
- Conditions
- Diabetic Foot, Diabetic Foot Ulcer, Diabetic Foot Ulcer Neuropathic
- Trial name
- NCT06003530
- Testing
- hOMSC200
- Where
- Israel
- Volunteers
- 21 people
- Sponsor
- Cytora Ltd.
Testicular Injury, Oligospermia
Safety of Cultured Allogeneic Adult Umbilical Cord Derived Mesenchymal Stem Cells for Testicular Injury and Oligospermia
This trial will study the safety and efficacy of intravenous infusion of cultured allogeneic adult umbilical cord derived mesenchymal stem cells for the treatment of Testicular Injury and Oligospermia
- Trial name
- NCT05158114
- Testing
- AlloRx
- Where
- Antigua and Barbuda
- Sponsor
- The Foundation for Orthopaedics and Regenerative Medicine
Leukemia, Lymphoma
Busulfan-fludarabine Conditioning and T-cell Depleted Allogeneic Stem Cell Transplantation for Patients With Advanced Hematologic Malignancies
The purpose of this study is: 1. To establish the maximally tolerated dose (MTD) of intravenous busulfan (Busulfan®) in combination with fludarabine as conditioning regimen for transplantation with in-vivo T-cell depletion. 2.
- Conditions
- Leukemia, Lymphoma, Myeloma
- Trial name
- NCT00943319
- Testing
- Busulfan, Fludarabine, Campath
- Where
- United States
- Volunteers
- 50 people
- Sponsor
- University of Chicago
Hematological Malignancies
Expanded Access of Omidubicel, for Allogeneic Transplantation in Patients With Hematological Malignancies
Omidubicel is an investigational therapy for patients with high-risk hematologic malignancies.
- Trial name
- NCT04260698
- Testing
- omidubicel
- Where
- 6 sites in United States
- Volunteers
- 36 people
- Sponsor
- Gamida Cell ltd
Hematopoietic Stem Cell Transplantation (HSCT)
Comprehensive Palliative Care After Stem Cell Transplantation: a Feasability Study
People who receive an allogeneic stem cell transplant often face important physical and emotional challenges during their recovery.
- Trial name
- COMPAS (NCT07895693)
- Testing
- Early Integrated Palliative Care
- Where
- Switzerland
- Volunteers
- 42 people
- Sponsor
- Lisa Hentsch
Sickle Cell Disease
Adding Azathioprine/Hydroxyurea Preconditioning to Alemtuzumab/TBI to Reduce Risk of Graft Failure in MSD HSCT in Adult SCD Patients
In this study the investigators will prospectively investigate whether the addition of a 3-months long preconditioning with azathioprine to the alemtuzumab/TBI non-myeloablative conditioning results in improved disease-free…
- Trial name
- NCT05249452
- Testing
- Preconditioning with azathiprine and hydroxyurea (3 months)
- Where
- Netherlands
- Volunteers
- 20 people
- Sponsor
- Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)
MYELODYSPLASTIC SYNDROME; MDS, ACUTE MYELOID LEUKEMIA; AML
JSP191 Antibody Conditioning Regimen in MDS/AML Subjects Undergoing Allogenic Hematopoietic Stem Cell Transplantation
This is a Phase 1a/b study to evaluate the safety and tolerability of an antibody conditioning regimen known as JSP191, in combination with low dose radiation and fludarabine, in subjects with Myelodysplastic Syndrome (MDS) or…
- Trial name
- NCT04429191
- Testing
- Humanized anti-CD117 Monoclonal Antibody (JSP191)
- Where
- 6 sites in United States
- Volunteers
- 32 people
- Sponsor
- Jasper Therapeutics, Inc.
Acute Myelocytic Leukemia, Myelodysplastic Syndromes
Decitabine Augments for Post Allogeneic Stem Cell Transplantation in Patients With Acute Myeloid Leukemia and Myelodysplastic Syndrome
Allo - hematopoietic stem cell transplantation is currently the only way to cure myelodysplastic syndrome /acute leukemia . The existing experimental results showed that decitabine and 5-azacytidine up-regulated the expression of…
- Trial name
- NCT01809392
- Testing
- decitabine
- Where
- China
- Volunteers
- 15 people, healthy volunteers welcome
- Sponsor
- The First Affiliated Hospital of Soochow University
Foot Deformities, Acquired, Disorder of Joint of Foot
A Clinical Study of Outcomes in Foot and Ankle Bone Grafting Using map3® Cellular Allogeneic Bone Graft
This is a single arm pilot study in patients requiring surgical fusion in the foot or ankle. Patients will receive map3® Cellular Allogeneic Bone Graft containing donor matched stem cells.
- Conditions
- Foot Deformities, Acquired, Disorder of Joint of Foot, Fracture of Foot, Deformity of Bone
- Trial name
- NCT02161016
- Testing
- map3
- Where
- United States
- Volunteers
- 1 people
- Sponsor
- RTI Surgical
Systemic Lupus Erythematosus
UCAR T-cell Therapy Targeting CD19/BCMA in Patients With r/r Systemic Lupus Erythematosus
This is an open label, single-site, dose-escalation study in up to 18 participants with relapsed or refractory Systemic lupus erythematosus.
- Trial name
- NCT06920433
- Testing
- UCAR T-cell group
- Where
- China
- Volunteers
- 18 people
- Sponsor
- Zhejiang University
Neuroblastoma
Allogeneic Tumor Cell Vaccination With Oral Metronomic Cytoxan in Patients With High-Risk Neuroblastoma
Neuroblastoma is the second most common solid tumor seen in children, but causes approximately 15% of childhood cancer deaths each year.
- Trial name
- ATOMIC (NCT01192555)
- Testing
- Neuroblastoma Vaccine (unmodified SKNLP, with gene-modified SJNB-JF-IL2 and SJNB-JF-LTN neuroblastoma cells, Cytoxan
- Where
- United States
- Volunteers
- 11 people
- Sponsor
- Baylor College of Medicine